Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Goldhirsch

Showing results (521-530 of 753) with videos related to

Pageof 76
Sort By:
Breast (Edinburgh, Scotland)|May 6, 2008
Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancerLaura Orlando, Barbara Del Curto, Sara Gandini, et al.
Cancer|May 21, 2011
Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patientsFilippo Montemurro, Valentina Rossi, Maria Cossu Rocca, et al.
Medical Care|March 1, 1996
Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trialC Hürny, J Bernhard, A Coates, et al.
Lancet (London, England)|April 20, 1996
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survivalR D Gelber, B F Cole, A Goldhirsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
CDX-2 should be included in the work-up of patients with lung metastases from unknown primaryN Fazio, T De Pas, F de Braud, et al.
Breast Cancer Research : BCR|June 22, 2014
Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypesPatrick Maisonneuve, Davide Disalvatore, Nicole Rotmensz, et al.
Anticancer Research|July 11, 2006
Vinorelbine-based chemotherapy in hormone-refractory prostate cancerM G Zampino, E Verri, M Locatelli, et al.
Clinical Breast Cancer|August 11, 2015
Outcome and Medial Presentation of Breast Cancer: European Institute of Oncology ExperienceEmilia Montagna, Vincenzo Bagnardi, Nicole Rotmensz, et al.
Anticancer Research|November 5, 2014
Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer?Gaetano Aurilio, Vincenzo Bagnardi, Rossella Graffeo, et al.
Breast (Edinburgh, Scotland)|June 30, 2022
Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51DR Graffeo, H Q Rana, F Conforti, et al.
Pageof 76

Showing results (521-530 of 753) with videos related to

Sort By:
Pageof 76
Breast (Edinburgh, Scotland)|May 6, 2008
Topoisomerase IIalpha gene status and prediction of pathological complete remission after anthracycline-based neoadjuvant chemotherapy in endocrine non-responsive Her2/neu-positive breast cancerLaura Orlando, Barbara Del Curto, Sara Gandini, et al.
Cancer|May 21, 2011
Hormone-receptor expression and activity of trastuzumab with chemotherapy in HER2-positive advanced breast cancer patientsFilippo Montemurro, Valentina Rossi, Maria Cossu Rocca, et al.
Medical Care|March 1, 1996
Responsiveness of a single-item indicator versus a multi-item scale: assessment of emotional well-being in an international adjuvant breast cancer trialC Hürny, J Bernhard, A Coates, et al.
Lancet (London, England)|April 20, 1996
Adjuvant chemotherapy plus tamoxifen compared with tamoxifen alone for postmenopausal breast cancer: meta-analysis of quality-adjusted survivalR D Gelber, B F Cole, A Goldhirsch, et al.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|November 20, 2004
CDX-2 should be included in the work-up of patients with lung metastases from unknown primaryN Fazio, T De Pas, F de Braud, et al.
Breast Cancer Research : BCR|June 22, 2014
Proposed new clinicopathological surrogate definitions of luminal A and luminal B (HER2-negative) intrinsic breast cancer subtypesPatrick Maisonneuve, Davide Disalvatore, Nicole Rotmensz, et al.
Anticancer Research|July 11, 2006
Vinorelbine-based chemotherapy in hormone-refractory prostate cancerM G Zampino, E Verri, M Locatelli, et al.
Clinical Breast Cancer|August 11, 2015
Outcome and Medial Presentation of Breast Cancer: European Institute of Oncology ExperienceEmilia Montagna, Vincenzo Bagnardi, Nicole Rotmensz, et al.
Anticancer Research|November 5, 2014
Does immediate breast reconstruction after mastectomy and neoadjuvant chemotherapy influence the outcome of patients with non-endocrine responsive breast cancer?Gaetano Aurilio, Vincenzo Bagnardi, Rossella Graffeo, et al.
Breast (Edinburgh, Scotland)|June 30, 2022
Moderate penetrance genes complicate genetic testing for breast cancer diagnosis: ATM, CHEK2, BARD1 and RAD51DR Graffeo, H Q Rana, F Conforti, et al.
Pageof 76